Průtoková cytometrie u monoklonálních gamapatií

Technologický rozvoj průtokové cytometrie (flow cytometry, FC) spolu s nejnovějšími poznatky z oblasti imunofenotypizace monoklonálních gamapatií (MG) odhalil nezbytnost tohoto vyšetření zejména pro jeho diagnostický, prognostický a prediktivní význam. Cílem Evropské myelomové sítě (European Myeloma Network, EMN) je standardizovat tuto analytickou metodu a zařadit ji mezi rutinní klinická vyšetření. Jelikož celkový význam a možné aplikace FC jsou stále analyzovány, je zřejmé, že standardizace může napomoci zisku relevantních klinických výstupů z oblasti patofyziologie MG.

Klíčová slova:
mnohočetný myelom – monoklonální gamapatie – průtoková cytometrie – plazmatická buňka

Tato práce byla podpořena granty Ministerstva školství, mládeže a tělovýchovy: LC06027, MSM0021622434; výzkumnými projekty IGA Ministerstva zdravotnictví: NT12425, NS10406, NS10408 a granty GAČR GAP304/10/1395, GP301/09/P457.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.

Autoři: L. Kovářová ^1,2; T. Varmužová ^1,2; P. Zarbochová ³; R. Suská ¹; Muthu Raja K. R. ^2,4; J. Štossová ²; M. Penka ⁴; R. Hájek ^1,2,5
Působiště autorů: Laboratory of Experimental Hematology and Cell Immunotherapy, Department of Clinical Hematology, University Hospital Brno, Czech Republic ¹; Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ²; Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic ³; Department of Clinical Hematology, University Hospital Brno, Czech Republic ⁴; Department of Internal Medicine – Hematooncology, University Hospital Brno, Czech Republic ⁵
Vyšlo v časopise: Klin Onkol 2011; 24(Supplementum 1): 24-29

Souhrn

Zdroje

1. Paiva B, Vidriales MB, Pérez JJ et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009; 94(11): 1599–1602.

2. Pérez-Persona E, Mateo G, García-Sanz R et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010; 148(1): 110–114.

3. Paiva B, Almeida J, Pérez-Andrés M et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010; 78(4): 239–252.

4. Rajkumar SV, Harousseau JL, Durie B et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117(18): 4691–4695.

5. Mateo G, Montalbán MA, Vidriales MB et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26(16): 2737–2744.

6. Johnsen HE, Bøgsted M, Klausen TW et al. Nordic Myeloma Study (NMSG). Myeloma Stem Cell Network (MSCNET). Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry B Clin Cytom 2010; 78(5): 338–347.

7. Rawstron AC, Orfao A, Beksac M et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93(3): 431–438.

8. Kovarova L, Buresova I, Suska R et al. Comparison of plasma cells phenotype in MGUS and MM. Brno: 4th Myeloma and 2nd Immunotherapy workshop 2009.

9. Kovarova L, Varmuzova T, Zarbochova P et al. Is Flow Cytometry Able to Distinguish Monoclonal Gammopathies and/or Multiple Myeloma Subtypes with Good Prognosis? Brno: 5th Myeloma workshop 2010.

10. Yang Y, Yaccoby S, Liu W et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002; 100(2): 610–617.

11. Caraux A, Klein B, Paiva B et al. Myeloma Stem Cell Network. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica 2010; 95(6): 1016–1020.

12. Bataille R, Jégo G, Robillard N et al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica 2006; 91(9): 1234–1240.

13. Cannizzo E, Bellio E, Sohani AR et al. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom 2010; 78(4): 231–238.

14. Kovarova L, Hajek R. Flow cytometric analysis of plasma cells in multiple myeloma. Klin Onkol 2008; 21 (Suppl 1): 249–252.

15. Ocqueteau M, Orfao A, Almeida J et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152(6): 1655–1665.

16. Sezer O, Heider U, Zavrski I et al. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica 2001; 86(8): 837–843.

17. Pérez-Persona E, Vidriales MB, Mateo G et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110(7): 2586–2592.

18. Paiva B, Vidriales MB, Mateo G et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009; 114(20): 4369–4372.

19. Kovarova L, Buresova I, Buchler T et al. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Neoplasma 2009; 56(6): 526–532.

20. Kovarova L, Buresova I, Suska R et al. Flow cytometric discrimination between neoplastic clonal and physiological polyclonal plasma cells. Klin Onkol 2008; 21 (Suppl 1): 254–257.

21. Rawstron AC, Davies FE, DasGupta R et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100(9): 3095–3100.

22. Sarasquete ME, García-Sanz R, González D et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005; 90(10): 1365–1372.

23. Paiva B, Vidriales MB, Cerveró J et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112(10): 4017–4023.

24. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149(3): 334–351.

25. Yuan CM, Stetler-Stevenson M. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma. Semin Hematol 2011; 48(1): 32–38.

26. Kovarova L, Buresova I, Raja KR et al. Expression of CD27 on plasma cells in multiple myeloma. Haematologica 2009; 94 (Suppl 2): 381.

27. Bataille R, Pellat-Deceunynck C, Robillard N et al. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2008; 32(3): 379–382.

28. Guikema JE, Hovenga S, Vellenga E et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol 2003; 121(1): 36–43.

29. Plowright EE, Li Z, Bergsagel PL et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000; 95(3): 992–928.

30. Grand EK, Chase AJ, Heath C et al. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004; 18(5): 962–966.

31. Hussein M, Berenson JR, Niesvizky R et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95(5): 845–848.

32. Marsee DK, Li B, Dorfman DM. Single tube, six-color flow cytometric analysis is a sensitive and cost-effective technique for assaying clonal plasma cells. Am J Clin Pathol 2010; 133(5): 694–699.

33. Chandesris MO, Soulier J, Labaume S et al. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma. Br J Haematol 2007; 136(4): 609–614.

34. López-Corral L, Gutiérrez NC, Vidriales MB et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 2011; 17(7): 1692–1700.

35. Perez-Andres M, Almeida J, Martin-Ayuso M et al. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. Int J Cancer 2009; 124(2): 367–375.

36. Katz BZ. Adhesion molecules. The lifelines of multiple myeloma cells. Semin Cancer Biol 2010; 20(3): 186–195.

37. Iqbal MS, Otsuyama K, Shamsasenjan K et al. Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow. Eur J Haematol 2009; 83(4): 302–312.

38. Vincent T, Mechti N. IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 2004; 18(5): 967–975.

39. Perez-Andres M, Paiva B, Nieto WG et al. Primary Health Care Group of Salamanca for the Study of MBL. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010; 78 (Suppl 1): S47–S60.

40. Agarwal JR, Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem 2010; 10(2): 116–120.

41. Svachova H, Pour L, Sana J et al. Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients. Leuk Res 2011. Epub ahead of print.

42. Maecker HT, Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A 2006; 69(9): 1037–1042.

43. Donnenberg AD, Donnenberg VS. Rare-event analysis in flow cytometry. Clin Lab Med 2007; 27(3): 627–652.

44. Maecker HT, Frey T, Nomura LE et al. Selecting fluorochrome conjugates for maximum sensitivity. Cytometry A 2004; 62(2): 169–173.

45. Morice WG, Chen D, Kurtin PJ et al. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström‘s macroglobulinemia. Mod Pathol 2009; 22(6): 807–816.

46. Meyerson HJ, Bailey J, Miedler J et al. Marginal zone B cell lymphomas with extensive plasmacytic differentiation are neoplasms of precursor plasma cells. Cytometry B Clin Cytom 2011; 80(2): 71–82.